Objectives To develop a population model to describe the pharmacokinetics (PK) of
intravenous meropenem in adult patients with severe burns and investigate potential …

Objectives To develop a population pharmacokinetic model of meropenem in burn patients
and to explore the appropriateness of current dosage regimens. Patients and methods Fifty …

Objectives Infections caused by multidrug-resistant Gram-negative bacteria are associated
with high mortality. A relevant concern is the efficacy of antibiotic therapy in burn patients in …

The objectives of this study were to develop a meropenem population pharmacokinetic
model using patient data and use it to explore alternative dosage regimens that could …

Population pharmacokinetic analyses can be applied to predict optimized dosages for
individual patients. The aim of this study was to compare the prediction performance of the …

Background: Meropenem is an effective β-lactam antibiotic that is frequently used to treat
serious infections in both intensive care unit (ICU) and febrile neutropenic …

Background Due to high pharmacokinetic variability, standard doses of meropenem are
frequently inadequate in septic patients. Therapeutic drug monitoring of meropenem is not …

Objectives To compare the plasma and subcutaneous tissue concentration–time profiles of
meropenem administered by intermittent bolus dosing or continuous infusion to critically ill …

Background Optimal anti-bacterial activity of meropenem requires maintenance of its plasma
concentration (Cp) above the minimum inhibitory concentration (MIC) of the pathogen for at …

Introduction Severe burn injury involves widespread skin and tissue damage leading to
systemic inflammation, hypermetabolism and multi‐organ failure. The hypermetabolic phase …